 |
|
|
| |
Map of GDF Countries Updated: 8 June 2006
GDF is ISO 9001:2000 compliant for provision of
quality-assured anti-TB drugs and related services to
eligible national TB control programmes.
|
|
|
 |
 |
|
Welcome to the Global Drug Facility
|
The Global Drug Facility (GDF) is a mechanism to expand access to, and availability of, high-quality anti-TB drugs and diagnostics to facilitate global DOTS expansion or maintenance to support the Stop TB Strategy.
New Long-Term Agreements (LTAs) with first-line TB drug suppliers and improved pricing system
19 February, 2008
From September through December 2007 the Global Drug Facility (GDF) conducted a competitive selection process among pre-qualified first-line drug manufacturers through its Procurement Agent, GTZ.
This competitive process is now complete, and GDF and GTZ are pleased to announce that awards have been made to five suppliers. Four of them - Svizera, Cadila, Strides and Lupin - were already serving as GDF suppliers. One new supplier, Macleods, also was selected. This expansion in the supplier pool indicates strong interest and competition among manufacturers, and augurs well for favourable pricing and availability of high quality anti-TB drugs.
GDF and GTZ have also introduced a new pricing system for first-line drugs that provides firmer estimates of total costs. Through consultation and cooperation with its agents, GDF is now able to list prices inclusive of quality assurance (QA) and Procurement Agent (PA) costs - a move that will aid clients in their budgeting and planning and lead to a more efficient drug procurement process.
GDF is committed to providing affordable high-quality anti-tuberculosis (TB) drugs to countries with a high TB burden and stimulating capacity and competition in the production sector.
STOP TB PARTNERSHIP AND UNITAID JOIN FORCES TO ADDRESS ANTI-TUBERCULOSIS DRUG SHORTFALLS
8 October 2007
Geneva -- The Stop TB Partnership's Global Drug Facility and UNITAID today announced a collaboration with 19 countries to address life-threatening shortages of anti-tuberculosis (TB) drugs. The initiative will provide these drugs to countries that are scaling up their TB control efforts and have confirmed future support from the Global Fund to Fight AIDS, Tuberculosis and Malaria or another donor but are not able to cover their full needs at present.
"This collaboration will deliver drugs to more than three-quarters of a million people who otherwise might not get treatment or could have their treatment interrupted because no drugs were available," said Dr Marcos Espinal, Executive Secretary of the Stop TB Partnership. "Getting anti-TB drugs to people who need them and making sure they complete their treatment is the best weapon we have for preventing drug-resistant TB."
The project, which is restricted to anti-TB treatments suitable for people whose form of TB is not resistant to standard therapies, also provides for the establishment of a stockpile of anti-TB drugs that will be made available to countries facing shortages because of humanitarian emergencies or inadequate capacity for planning orders.
Press release
Announcement of 18th Round of applications to the Global Drug Facility
1 February, 2008
The eighteenth round of applications to the Global Drug Facility (GDF) is now open and the GDF Secretariat is accepting applications from governments for grants of free first-line adult and paediatric anti-tuberculosis drugs. The closing date for receipt of applications is Wednesday 5 March 2008.
French  ,
English
Request for expressions of interest for manufacturers of second-line anti-TB drugs
9 October, 2007
The Global Drug Facility (GDF) is looking to increase the access to quality, affordably priced second-line anti-TB drugs to be supplied to Green Light Committee (GLC) approved programs. GDF in collaboration with the USP (United States Pharmacopeia) and USAID (US Agency for International Development) is interested to receive Expressions of Interest from manufacturers of second line anti-TB drugs who would benefit from receiving technical assistance to enable them to rapidly conform to WHO recommended standards.
Manufacturers for the following products are encouraged to submit their expression of interest to the Global Drug Facility for technical assistance: 1) Capreomycin 1 g, powder for injection, 2) Kanamycin 1 g, powder for injection; 3) Para-amino salicylic acid 4 g or its sodium salt 100 g, coated-granules.
Interested manufacturers should send a cover letter and the questionnaire below, duly completed, to the GDF before 29 October 2007 (17:00 Geneva, Switzerland).
Download EOI
Download Questionnaire 
Global Drug Facility delivers tuberculosis treatments for 10 million people in six years
29 May, 2007
The Stop TB Partnership announced today that its drug supply arm, the Global Drug Facility, has provided anti-TB drug treatments for 10 million people to 78 countries in the past six years. A reliable supply of drugs is crucial both for preventing deaths from this often lethal disease and for fighting the spread of drug-resistant TB. Click here to read more.
Statements of support for GDF
GDF Achievements Report: 10 Million Treatments Supplied in 6 Years
New publication: "The Design and In-Country Evaluation of TB Diagnostic Laboratory Kits"
April, 2007
GDF and Management Sciences for Health have piloted and evaluated diagnostic laboratory kits for tuberculosis (TB) in three countries - The Republic of the Congo, Nigeria, and Tajikistan. The new publication "The Design and In-Country Evaluation of TB Diagnostic Laboratory Kits" describes the objectives of the evaluation, the methodology and process used and the findings of the evaluation and final recommendations.
Islamic Republic of Afghanistan awards GDF for its support
21 November, 2006
The Islamic Republic of Afghanistan's Ministry of Public Health has issued formal thanks to the GDF for "the outstanding Technical, Financial and Logistical support of GDF to the National TB Control Program for expanding Quality DOTS services in Afghanistan". The GDF is grateful for this recognition and in turn thanks the Ministry of Public Health for its own commitment to national TB control.
Since 2003 the GDF has been providing assistance to the Islamic Republic of Afghanistan's Ministry of Public Health through both its Grant and Direct Procurement services. As recently as March 2006 the GDF Technical Review Committee approved the Islamic Republic of Afghanistan for a 3-year grant of anti-TB drugs, which should be sufficient to treat approximately 38,000 patients in the grant's first year.
A new, innovative financing initiative, "UNITAID", enables GDF to offer grants of paediatric anti-TB drugs
October, 2006
This year, France, Brazil, Chile, Norway and the United-Kingdom (Core Group), with the backing of several international organizations, NGOs and private foundations have decided to join forces to help scale up access to treatment for
HIV/AIDS, Malaria and Tuberculosis for the poor in developing countries - through lowering the price of drugs and diagnostics and accelerating the pace at which they are made available. To do this, the Core Group established an innovative financing initiative: UNITAID, which will offer a unique opportunity to provide long-term support, thanks to sustainable, predictable funding.
Recognizing the success and effectiveness of GDF in supplying quality, low-cost 1st line adult anti-TB drugs and related support to over 60 countries in the past 5 years, UNITAID has identified GDF as the Programmatic Partner to implement the procurement and supply of paediatric anti-TB drugs.
|
|
|
